Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS 1/20 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris,Contraceptive for women with menstrual disorders
Prevention of pregnancy (FDA-approved)
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Both ethinyl estradiol and gestodene are metabolized primarily in the liver via the cytochrome P450 3A4 (CYP3A4) pathway. Ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation; gestodene is hydroxylated and conjugated.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinylestradiol: 98% bound to albumin. Gestodene: 75-90% bound to sex hormone-binding globulin (SHBG) and albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinylestradiol: ~2.4 L/kg. Gestodene: ~0.7 L/kg. Indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinylestradiol ~40-60% (first-pass metabolism). Gestodene ~99% (highly bioavailable due to minimal first-pass effect).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild-to-moderate renal impairment. Insufficient data for severe renal impairment; use with caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in hepatic adenomas, active liver disease, or Child-Pugh class B/C cirrhosis. For mild hepatic impairment (Child-Pugh A), no dosage adjustment; monitor.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use in pediatric patients before menarche. Post-menarche, same as adult dosing; use only after establishment of regular menstrual cycles.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific geriatric dosing; generally not used in elderly women due to increased risk of thromboembolism.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is particularly pronounced in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Risk of thromboembolic disorders (venous and arterial), including myocardial infarction and stroke,Increased risk of hypertension and associated vascular complications,Potential hepatic neoplasia (benign and malignant),Possible exacerbation of cholestatic jaundice or gallbladder disease,May cause fluid retention, which can aggravate conditions such as migraine, asthma, cardiac, or renal dysfunction,Altered carbohydrate metabolism: monitor glucose in diabetic patients,May worsen depression or epilepsy
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or history of thrombosis (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke),History of cerebrovascular accident,Current or history of breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Active liver disease or impaired liver function,Hypersensitivity to any component of the product,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) at age ≥35,Major surgery with prolonged immobilization
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions are reported for GILDESS 1/20. However, grapefruit juice may increase estrogen levels; advise patients to consume grapefruit products in moderation. Alcohol may impair judgment regarding missed doses; recommend moderate intake.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction) from estrogen component; cardiovascular and nervous system malformations reported. Second and third trimesters: associated with masculinization of female fetus from progestin; increased risk of IUGR and preterm birth. Use contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk; ethinyl estradiol M/P ratio ~0.4, desogestrel M/P ratio ~0.6. May reduce milk quantity and quality; small amounts pose theoretical risk of estrogenic effects in infant. Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, increased renal clearance) would reduce efficacy, but use is not recommended.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
GILDESS 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. It is indicated for contraception and may be used for acne vulgaris in women at least 15 years old. Monitor for breakthrough bleeding, especially in the first cycles. Counsel patients to take at the same time daily to maintain efficacy. Caution in women with migraine with aura, hypertension, or history of thromboembolism. Prescribe as a 21-day regimen with a 7-day hormone-free interval.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time every day, even if you do not have sex often.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider.,Use a backup method (like condoms) if you miss more than one pill or start late.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few cycles.,Contact your doctor if you experience severe abdominal pain, chest pain, headache, vision changes, or leg pain/swelling.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking while on this medication.,Do not take GILDESS if you are pregnant or suspect pregnancy.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS 1/20 vs AFIRMELLE, answered by our medical review team.
GILDESS 1/20 is a Oral Contraceptive that works by GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS 1/20 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS 1/20 is: One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS 1/20 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS 1/20 is classified as Category C. GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.